These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 11902305)

  • 41. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
    Aygun B; Mortier NA; Smeltzer MP; Shulkin BL; Hankins JS; Ware RE
    Am J Hematol; 2013 Feb; 88(2):116-9. PubMed ID: 23255310
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.
    Lopes FC; Traina F; Almeida CB; Leonardo FC; Franco-Penteado CF; Garrido VT; Colella MP; Soares R; Olalla-Saad ST; Costa FF; Conran N
    Haematologica; 2015 Jun; 100(6):730-9. PubMed ID: 25769545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
    Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
    Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enalapril and hydroxyurea therapy for children with sickle nephropathy.
    Fitzhugh CD; Wigfall DR; Ware RE
    Pediatr Blood Cancer; 2005 Dec; 45(7):982-5. PubMed ID: 15704213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study.
    Wang WC; Helms RW; Lynn HS; Redding-Lallinger R; Gee BE; Ohene-Frempong K; Smith-Whitley K; Waclawiw MA; Vichinsky EP; Styles LA; Ware RE; Kinney TR
    J Pediatr; 2002 Feb; 140(2):225-9. PubMed ID: 11865275
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Should we still be focused on red cell hemoglobin F as the principal explanation for the salutary effect of hydroxyurea in sickle cell disease?
    Segel GB; Simon W; Lichtman MA
    Pediatr Blood Cancer; 2011 Jul; 57(1):8-9. PubMed ID: 21480473
    [No Abstract]   [Full Text] [Related]  

  • 48. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children.
    Estepp JH; Smeltzer MP; Wang WC; Hoehn ME; Hankins JS; Aygun B
    Br J Haematol; 2013 May; 161(3):402-5. PubMed ID: 23384083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.
    Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A
    Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hydroxyurea therapy decreases coagulation and endothelial activation in sickle cell disease: a Longitudinal Study.
    Elsherif L; Scott LC; Wichlan D; Jones SK; Mathias JG; Shen JH; Smeltzer MP; Ataga KI
    Br J Haematol; 2021 Aug; 194(3):e71-e73. PubMed ID: 34231209
    [No Abstract]   [Full Text] [Related]  

  • 51. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hydroxyurea and follicle density in sickle cell.
    Creary S; Kebodeaux C; Nahata L
    Blood Adv; 2024 Oct; 8(19):5225-5226. PubMed ID: 39378027
    [No Abstract]   [Full Text] [Related]  

  • 53. Immunologic effects of hydroxyurea in sickle cell anemia.
    Lederman HM; Connolly MA; Kalpatthi R; Ware RE; Wang WC; Luchtman-Jones L; Waclawiw M; Goldsmith JC; Swift A; Casella JF;
    Pediatrics; 2014 Oct; 134(4):686-95. PubMed ID: 25180279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 55. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
    Tolu SS; Crouch A; Choi J; Gao Q; Reyes-Gil M; Ogu UO; Vinces G; Minniti CP
    Ann Hematol; 2022 Mar; 101(3):541-548. PubMed ID: 35039901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
    Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM
    Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hydroxyurea Improves Oxygen Saturation in Children With Sickle Cell Disease.
    Pashankar FD; Manwani D; Lee MT; Green NS
    J Pediatr Hematol Oncol; 2015 Apr; 37(3):242-3. PubMed ID: 25222060
    [No Abstract]   [Full Text] [Related]  

  • 58. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P; Barretto de Mello A; Figueiredo MS
    Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.
    Narang I; Kadmon G; Lai D; Dhanju S; Kirby-Allen M; Odame I; Amin R; Lu Z; Al-Saleh S
    Ann Am Thorac Soc; 2015 Jul; 12(7):1044-9. PubMed ID: 25970812
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.